Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - aġenti antineoplastiċi oħra - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - aġenti antineoplastiċi - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - majloma multipla - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infezzjonijiet ta 'virus sintetiku respiratorju - vaċċini - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. ara t-taqsimiet 4. 2 u 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosoppressanti - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - aġenti antitrombotiċi - clopidogrel huwa indikat fl-adulti għall-prevenzjoni ta 'avvenimenti aterotrombotiċi f': pazjenti li jbatu minn infart mijokardijaku (minn ftit jiem sa inqas minn 35 jum), puplesija iskemika (minn 7 ijiem sa inqas minn 6 xhur) jew mard arterjali periferali;il-pazjenti li jbatu mis-sindromu koronarju akut:- nuqqas ta elevazzjoni tas-segment st sindromu koronarju akut (anġina instabbli jew mhux-mewġa-q infart mijokardijaku), li jinkludu pazjenti fi proċess li titpoġġa stent wara intervent koronarju perkutanju, flimkien ma ' acetylsalicylic acid (asa);l - elevazzjoni tas-segment st infart mijokardijaku akut, flimkien ma ' asa f'medikament pazjenti kkurati b'eliġibbli għat-terapija trombolitika. għall-aktar informazzjoni jekk jogħġbok irreferi għal sezzjoni 5.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - aġenti antitrombotiċi - clopidogrel huwa indikat fl-adulti għall-prevenzjoni tal-ġrajjiet atherothrombotic f: * pazjenti li jsofru minn myocardial infarzjoni (minn ftit ġranet sa inqas minn 35 jum), ischaemic stroke (minn 7 ijiem sa inqas minn 6 xhur) jew stabbilit periferali mard arterjali. għall-aktar informazzjoni jekk jogħġbok irreferi għal sezzjoni 5.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

1 a pharma gmbh - rivastigmine - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - trattament sintomatiku ta 'dimenzja ta' alzheimer ħafifa għal moderatament gravi. kura sintomatika ta 'minn ħafifa għal moderatament gravi dimenzja f'pazjenti bil-marda idjopatika ta' parkinson.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

hexal ag  - rivastigmine - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - trattament sintomatiku ta 'dimenzja ta' alzheimer ħafifa għal moderatament gravi. kura sintomatika ta 'minn ħafifa għal moderatament gravi dimenzja f'pazjenti bil-marda idjopatika ta' parkinson.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

emdoka bvba - halofuginone lactate - halofuginone, oħra proto \ - aġenti tal - - għoġġiela, twelid - fl-għoġġiela tat-twelid:il-prevenzjoni ta 'dijarea \ ata minn cryptosoridium pavarum infezzjoni, f'irziezet bi storja ta' il-kriptosporidjosi. l-amministrazzjoni għandha tibda fl-ewwel 24 sa 48 siegħa. it-tnaqqis tad-dijarea \ ata minn cryptosoridium pavarum infezzjoni. l-amministrazzjoni għandha tibda fi żmien 24 siegħa wara l-bidu tad-dijarea. fiż-żewġ każijiet, it-tnaqqis ta 'l-eliminazzjoni ta' l-ooċisti intwera.